This study tests a new drug called HCB101 combined with standard cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. The goal is to find the safest dose and see if the combination can shrink tumors. About 500 adults with various …
Phase: PHASE1, PHASE2 • Sponsor: FBD Biologics Limited • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC